Arthritis and rheumatism最新文献

{"title":"Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.","authors":"Mandana Nikpour,&nbsp;Murray B Urowitz,&nbsp;Dominique Ibañez,&nbsp;Dafna D Gladman","doi":"10.1002/art.24741","DOIUrl":"https://doi.org/10.1002/art.24741","url":null,"abstract":"<p><strong>Objective: </strong>Selection of flare as the primary outcome variable in systemic lupus erythematosus (SLE) clinical trials fails to capture patients with persistently active disease (PAD). We sought to elucidate the frequency and determinants of flare and PAD.</p><p><strong>Methods: </strong>Prospectively collected data from the Toronto Lupus Cohort were used to determine the incidence of flare and PAD in 2004 and 2005. Flare was defined as an increase in SLE Disease Activity Index 2000 update (SLEDAI-2K) score of >/=4 from the previous visit. PAD was defined as a SLEDAI-2K score of >/=4, excluding serology alone, on >/=2 consecutive visits. Data from 1, 2, and 3 years prior were used to model flare and PAD in 2004. Model properties were tested for prediction of flare and PAD in 2005.</p><p><strong>Results: </strong>One-third of the patients had >/=1 flare, whereas nearly half experienced PAD in a given year. Nearly 60% of the patients had episodes of flare or PAD per year. At least 25% of patients had PAD without achieving the definition of flare. In the best-fitting model, predictors of PAD in 2004 were SLEDAI-2K score at the start of the outcome interval and prior cutaneous or musculoskeletal disease activity. This model gave 79% correct prediction of PAD in 2005. In contrast, flare prediction models performed poorly.</p><p><strong>Conclusion: </strong>Persistent activity is a common disease state in SLE and should be an outcome variable in SLE clinical trials. Our PAD prediction model may aid prognostication and selection of patients for inclusion in clinical trials.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1152-8"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24741","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28370412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae.","authors":"Winston J Rennie,&nbsp;Suhkvinder S Dhillon,&nbsp;Barbara Conner-Spady,&nbsp;Walter P Maksymowych,&nbsp;Robert G W Lambert","doi":"10.1002/art.24561","DOIUrl":"https://doi.org/10.1002/art.24561","url":null,"abstract":"<p><strong>Objective: </strong>Radiologic assessment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic resonance imaging (MRI), although little is known about the distribution of inflammatory lesions within the structures of the spine. Our objective was to compare the distribution of inflammatory lesions centrally and laterally within the thoracic and lumbar spine vertebral bodies.</p><p><strong>Methods: </strong>We studied 49 patients with AS who were scanned with STIR and T1-weighted spin-echo MRI of the whole spine. Scans were read by 2 musculoskeletal radiologists, with a third reader as the arbitrator. Controls included 6 age-matched individuals. We recorded bone marrow edema on STIR images from each vertebral body, separately identifying central and lateral slices. The latter were defined as images that included or were lateral to the pedicle. Interreader reproducibility was assessed by kappa statistics.</p><p><strong>Results: </strong>Inflammation was present in 263 (45%) of 588 thoracic and 86 (35%) of 245 lumbar vertebrae; the mean number of affected thoracic and lumbar vertebrae per patient were 5.4 and 1.8, respectively. Inflammation was present in the lateral aspect of 219 (37%) of 588 thoracic vertebrae and 45 (18%) of 245 lumbar vertebrae (P < 0.001). Lesions were more common laterally than centrally for all thoracic vertebrae except for T7. Involvement of only the lateral slices was observed in as many as 19.6% of thoracic vertebrae.</p><p><strong>Conclusion: </strong>Evaluation of spinal inflammation by MRI may omit lesions in up to 20% of inflamed thoracic vertebrae if both scanning and image assessment do not include sagittal slices that extend to the lateral edges of all vertebrae.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1187-93"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24561","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28367669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis.","authors":"Jon T Giles,&nbsp;Matthew Allison,&nbsp;Clifton O Bingham,&nbsp;William M Scott,&nbsp;Joan M Bathon","doi":"10.1002/art.24789","DOIUrl":"https://doi.org/10.1002/art.24789","url":null,"abstract":"<p><strong>Objective: </strong>Recent reports have suggested that increasing adiposity may protect against radiographic damage in rheumatoid arthritis (RA). We explored the role of serum adipokines (adiponectin, resistin, and leptin) in mediating this association.</p><p><strong>Methods: </strong>Patients with RA underwent total-body dual x-ray absorptiometry for measurement of total and regional body fat and lean mass, abdominal computed tomography for measurement of visceral fat area, and radiographs of the hands and feet scored according to the modified Sharp/van der Heijde (SHS) method. Serum levels of adipokines were measured and cross-sectional associations with radiographic damage were explored, adjusting for pertinent confounders. The associations of measures of adiposity with radiographic damage were explored with the introduction of adipokines into multivariable modeling as potential mediators.</p><p><strong>Results: </strong>Among the 197 patients studied, adiponectin demonstrated a strong association with radiographic damage, with the log SHS score increasing by 0.40 units for each log unit increase in adiponectin (P = 0.001) after adjusting for pertinent predictors of radiographic damage. Adiponectin independently accounted for 6.1% of the explainable variability in SHS score, a proportion comparable with rheumatoid factor, and greater than HLA-DRB1 shared epitope alleles or C-reactive protein levels. Resistin and leptin were not associated with radiographic damage in adjusted models. An inverse association between visceral fat area and radiographic damage was attenuated when adiponectin was modeled as a mediator. The association of adiponectin with radiographic damage was stronger in patients with longer disease duration.</p><p><strong>Conclusion: </strong>Adiponectin may represent a mechanistic link between low adiposity and increased radiographic damage in RA. Adiponectin modulation may represent a novel strategy for attenuating articular damage.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1248-56"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24789","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28369388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.","authors":"Dinesh Khanna,&nbsp;Ron D Hays,&nbsp;Paul Maranian,&nbsp;James R Seibold,&nbsp;Ann Impens,&nbsp;Maureen D Mayes,&nbsp;Philip J Clements,&nbsp;Terri Getzug,&nbsp;Nihal Fathi,&nbsp;Amber Bechtel,&nbsp;Daniel E Furst","doi":"10.1002/art.24730","DOIUrl":"https://doi.org/10.1002/art.24730","url":null,"abstract":"<p><strong>Objective: </strong>To refine the previously developed scleroderma (systemic sclerosis [SSc]) gastrointestinal tract (GIT) instrument (SSC-GIT 1.0).</p><p><strong>Methods: </strong>We administered the SSC-GIT 1.0 and the Short Form 36 to 152 patients with SSc; 1 item was added to the SSC-GIT 1.0 to assess rectal incontinence. In addition, subjects completed a rating of the severity of their GIT involvement (from very mild to very severe). Evaluation of psychometric properties included internal consistency reliability, test-retest reliability (mean time interval 1.1 weeks), and multitrait scaling analysis.</p><p><strong>Results: </strong>Study participants were mostly women (84%) and white (81%); 55% had diffuse SSc. Self-rated severity of GIT involvement ranged from no symptoms to very mild (39%), mild (21%), moderate (31%), and severe/very severe (9%). Of an initial 53 items in the SSC-GIT 1.0, 19 items were excluded, leaving a 34-item revised instrument (the University of California, Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 [UCLA SCTC GIT 2.0]). Analyses supported 7 multi-item scales: reflux, distention/bloating, diarrhea, fecal soilage, constipation, emotional well-being, and social functioning. Test-retest reliability estimates were >/=0.68 and coefficient alphas were >/=0.67. Participants who rated their GIT disease as mild had lower scores on a 0-3 scale on all 7 scales. Symptom scales were also able to discriminate subjects with corresponding clinical GIT diagnoses. The Total GIT Score, developed by averaging 6 of 7 scales (excluding constipation), was reliable and provided greater discrimination between mild, moderate, and severe self-rated GIT involvement than individual scales.</p><p><strong>Conclusion: </strong>This study provides support for the reliability and validity of the UCLA SCTC GIT 2.0, an improvement over the SSC-GIT 1.0, and supports a Total GIT Score in SSc patients with GIT.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1257-63"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24730","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28370410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.","authors":"Daniel J Wallace,&nbsp;William Stohl,&nbsp;Richard A Furie,&nbsp;Jeffrey R Lisse,&nbsp;James D McKay,&nbsp;Joan T Merrill,&nbsp;Michelle A Petri,&nbsp;Ellen M Ginzler,&nbsp;W Winn Chatham,&nbsp;W Joseph McCune,&nbsp;Vivian Fernandez,&nbsp;Marc R Chevrier,&nbsp;Z John Zhong,&nbsp;William W Freimuth","doi":"10.1002/art.24699","DOIUrl":"https://doi.org/10.1002/art.24699","url":null,"abstract":"<p><strong>Objective: </strong>To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE).</p><p><strong>Methods: </strong>Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score >/=4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo in a 52-week study. Coprimary end points were the percent change in the SELENA-SLEDAI score at week 24 and the time to first SLE flare.</p><p><strong>Results: </strong>Significant differences between the treatment and placebo groups were not attained for either primary end point, and no dose response was observed. Reductions in SELENA-SLEDAI scores from baseline were 19.5% in the combined belimumab group versus 17.2% in the placebo group. The median time to first SLE flare was 67 days in the combined belimumab group versus 83 days in the placebo group. However, the median time to first SLE flare during weeks 24-52 was significantly longer with belimumab treatment (154 versus 108 days; P = 0.0361). In the subgroup (71.5%) of serologically active patients (antinuclear antibody titer >/=1:80 and/or anti-double-stranded DNA [anti-dsDNA] >/=30 IU/ml), belimumab treatment resulted in significantly better responses at week 52 than placebo for SELENA-SLEDAI score (-28.8% versus -14.2%; P = 0.0435), physician's global assessment (-32.7% versus -10.7%; P = 0.0011), and Short Form 36 physical component score (+3.0 versus +1.2 points; P = 0.0410). Treatment with belimumab resulted in a 63-71% reduction of naive, activated, and plasmacytoid CD20+ B cells, and a 29.4% reduction in anti-dsDNA titers (P = 0.0017) by week 52. The rates of adverse events and serious adverse events were similar in the belimumab and placebo groups.</p><p><strong>Conclusion: </strong>Belimumab was biologically active and well tolerated. The effect of belimumab on the reduction of SLE disease activity or flares was not significant. However, serologically active SLE patients responded significantly better to belimumab therapy plus SOC than to SOC alone.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1168-78"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24699","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28370414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients.","authors":"Stephen E Gwilym,&nbsp;John R Keltner,&nbsp;Catherine E Warnaby,&nbsp;Andrew J Carr,&nbsp;Boris Chizh,&nbsp;Iain Chessell,&nbsp;Irene Tracey","doi":"10.1002/art.24837","DOIUrl":"https://doi.org/10.1002/art.24837","url":null,"abstract":"<p><strong>Objective: </strong>The groin pain experienced by patients with hip osteoarthritis (OA) is often accompanied by areas of referred pain and changes in skin sensitivity. We aimed to identify the supraspinal influences that underlie these clinical manifestations that we consider indicative of possible central sensitization.</p><p><strong>Methods: </strong>Twenty patients with hip OA awaiting joint replacement and displaying signs of referred pain were recruited into the study, together with age-matched controls. All subjects completed pain psychology questionnaires and underwent quantitative sensory testing (QST) in their area of referred pain. Twelve of 20 patients and their age- and sex-matched controls underwent functional magnetic resonance imaging (MRI) while the areas of referred pain were stimulated using cold stimuli (12 degrees C) and punctate stimuli (256 mN). The remaining 8 of 20 patients underwent punctate stimulation only.</p><p><strong>Results: </strong>Patients were found to have significantly lower threshold perception to punctate stimuli and were hyperalgesic to the noxious punctate stimulus in their areas of referred pain. Functional brain imaging illustrated significantly greater activation in the brainstem of OA patients in response to punctate stimulation of their referred pain areas compared with healthy controls, and the magnitude of this activation positively correlated with the extent of neuropathic-like elements to the patient's pain, as indicated by the PainDETECT score.</p><p><strong>Discussion: </strong>Using psychophysical (QST) and brain imaging methods (functional MRI), we have identified increased activity with the periaqueductal grey matter associated with stimulation of the skin in referred pain areas of patients with hip OA. This offers a central target for analgesia aimed at improving the treatment of this largely peripheral disease.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1226-34"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24837","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28369384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 65-year-old man with longstanding seropositive rheumatoid arthritis and lower extremity ulceration.","authors":"Samar Charabaty,&nbsp;Victoria Shanmugam","doi":"10.1002/art.24700","DOIUrl":"https://doi.org/10.1002/art.24700","url":null,"abstract":"","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1275-80"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24700","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28370406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do psychological characteristics predict response to exercise and advice for subacute low back pain?","authors":"Rob J E M Smeets,&nbsp;Chris G Maher,&nbsp;Michael K Nicholas,&nbsp;Kathy M Refshauge,&nbsp;Robert D Herbert","doi":"10.1002/art.24731","DOIUrl":"https://doi.org/10.1002/art.24731","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether psychological characteristics predict outcome and/or response to physiotherapist-directed exercise- or advice-based treatment of subacute low back pain.</p><p><strong>Methods: </strong>We conducted a secondary analysis of a factorial, placebo-controlled trial (n = 259). The psychological characteristics were catastrophizing, coping, pain self-efficacy, fear of injury/movement, depression, anxiety, and stress. We used mixed models to predict pain and function outcomes (both scored on a 0-10 scale). The models include a term for treatment group, a term for the psychological characteristic (which tested prediction of outcome), and an interaction term between the treatment group and psychological characteristic (which tested treatment effect modification). To aid the interpretation of the magnitude of the effect modification, we calculated the change in outcome for a 1 SD increase of the baseline score of the putative effect modifier. A >/=1.5-point change of the outcome of interest per 1 SD change of putative effect modifier was regarded as clinically important.</p><p><strong>Results: </strong>All of the psychological characteristics except coping predicted outcome, but none appeared to be important treatment effect modifiers. Only 5 of the 56 tests of treatment modification were statistically significant, and none of the 95% confidence intervals (95% CIs) for the interactions included clinically important effects. For example, a 1 SD higher baseline level of anxiety was associated with a 0.62 (95% CI 0.10, 1.15) additional effect of exercise on function at 52 weeks.</p><p><strong>Conclusion: </strong>Most of the psychological characteristics we tested predicted outcome, but none predicted response to physiotherapist-guided exercise and/or advice.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1202-9"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28370411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel evidence-based systemic lupus erythematosus responder index.","authors":"Richard A Furie, Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William Stohl, W Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R Chevrier, Z John Zhong, William W Freimuth","doi":"10.1002/art.24698","DOIUrl":"10.1002/art.24698","url":null,"abstract":"<p><strong>Objective: </strong>To describe a new systemic lupus erythematosus (SLE) responder index (SRI) based on a belimumab phase II SLE trial and demonstrate its potential utility in SLE clinical trials.</p><p><strong>Methods: </strong>Data from a randomized, double-blind, placebo-controlled study in 449 patients of 3 doses of belimumab (1, 4, 10 mg/kg) or placebo plus standard of care therapy (SOC) over a 56-week period were analyzed. The Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and British Isles Lupus Assessment Group (BILAG) SLE disease activity instruments, the Short Form 36 health survey, and biomarker analyses were used to create a novel SRI. Response to treatment in a subset of 321 serologically active SLE patients (antinuclear antibodies >/=1:80 and/or anti-double-stranded DNA antibodies >/=30 IU/ml) at baseline was retrospectively evaluated using the SRI.</p><p><strong>Results: </strong>SRI response is defined as 1) a >/=4-point reduction in SELENA-SLEDAI score, 2) no new BILAG A or no more than 1 new BILAG B domain score, and 3) no deterioration from baseline in the physician's global assessment by >/=0.3 points. In serologically active patients, the addition of belimumab to SOC resulted in a response in 46% of patients at week 52 compared with 29% of the placebo patients (P = 0.006). SRI responses were independent of baseline autoantibody subtype.</p><p><strong>Conclusion: </strong>This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.</p>","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 9","pages":"1143-51"},"PeriodicalIF":0.0,"publicationDate":"2009-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748175/pdf/nihms118839.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28367675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibromyalgianess.","authors":"Frederick Wolfe","doi":"10.1002/art.24553","DOIUrl":"https://doi.org/10.1002/art.24553","url":null,"abstract":"","PeriodicalId":8405,"journal":{"name":"Arthritis and rheumatism","volume":"61 6","pages":"715-6"},"PeriodicalIF":0.0,"publicationDate":"2009-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/art.24553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28205395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}